Benefit-Risk Assessment of Medicines - The Development and Application of a Universal Framework for Decision-Making and Effective Communication (Paperback, Softcover reprint of the original 1st ed. 2015)

, ,
This book proposes and investigates a universal framework, and accompanying documentation system, to facilitate and catalogue benefit-risk decisions; a valuable addition to the benefit-risk toolbox. Over the past decade, pharmaceutical companies and regulatory agencies have been reviewing the benefit-risk assessment of medicines with a view to developing a structured, systematic, standardized approach. Examining the evaluation of such an approach by several mature regulatory authorities ensures that the reader gains a unique insight into the ongoing debate in this area. The field of benefit-risk assessment continues to evolve at a rapid pace due to political and societal pressure, as is reflected in the recent FDA PUDFA agreement as well as in the EMA 2015 Roadmap. Rather than provide a comprehensive snap-shot of this constantly changing environment, this book evaluates selected current approaches to benefit-risk assessment. The strengths and weaknesses of publicly available documents in communicating benefit-risk decisions to stakeholders are reviewed and these evaluations are used to inform development of a prospective framework that could be used to harmonise procedures globally.

R2,552

Or split into 4x interest-free payments of 25% on orders over R50
Learn more

Discovery Miles25520
Mobicred@R239pm x 12* Mobicred Info
Free Delivery
Delivery AdviceShips in 10 - 15 working days



Product Description

This book proposes and investigates a universal framework, and accompanying documentation system, to facilitate and catalogue benefit-risk decisions; a valuable addition to the benefit-risk toolbox. Over the past decade, pharmaceutical companies and regulatory agencies have been reviewing the benefit-risk assessment of medicines with a view to developing a structured, systematic, standardized approach. Examining the evaluation of such an approach by several mature regulatory authorities ensures that the reader gains a unique insight into the ongoing debate in this area. The field of benefit-risk assessment continues to evolve at a rapid pace due to political and societal pressure, as is reflected in the recent FDA PUDFA agreement as well as in the EMA 2015 Roadmap. Rather than provide a comprehensive snap-shot of this constantly changing environment, this book evaluates selected current approaches to benefit-risk assessment. The strengths and weaknesses of publicly available documents in communicating benefit-risk decisions to stakeholders are reviewed and these evaluations are used to inform development of a prospective framework that could be used to harmonise procedures globally.

Customer Reviews

No reviews or ratings yet - be the first to create one!

Product Details

General

Imprint

Adis International

Country of origin

Switzerland

Release date

October 2016

Availability

Expected to ship within 10 - 15 working days

First published

2015

Authors

, ,

Dimensions

235 x 155 x 18mm (L x W x T)

Format

Paperback

Pages

317

Edition

Softcover reprint of the original 1st ed. 2015

ISBN-13

978-3-319-36767-5

Barcode

9783319367675

Categories

LSN

3-319-36767-6



Trending On Loot